SynthesisBioMed research international2014
Tumour markers and kidney function: a systematic review.
Synthesis in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Predictive Factors of Non-Elevation of Carcinoembryonic Antigen 125 in Acute Heart Failure.Life (Basel, Switzerland) · 2025Article
- Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries.Discover oncology · 2025Review
- Predictive Value of Serum β2-Microglobulin for 28-Day Mortality in Sepsis Patients in the Emergency Department.Infection and drug resistance · 2025Article
- Cancer before and after the start of hemodialysis and association with mortality - an Eastern-European multicenter study.Renal failure · 2023Article
- CA125: a novel cardiac biomarker for infants with congenital diaphragmatic hernia.Pediatric research · 2023Article
- Changes in lung cancer-related serum tumor markers in patients with chronic kidney disease and determination of upper reference limit.Frontiers in oncology · 2022Article
- Low Albumin, Low Bilirubin, and High Alfa-Fetoprotein Are Associated with a Rapid Renal Function Decline in a Large Population Follow-Up Study.Journal of personalized medicine · 2021Article
- The Clinical Significance of DJ1 and L1CAM Serum Level Monitoring in Patients with Endometrial Cancer.Journal of clinical medicine · 2021Article
- Retarding Progression of Chronic Kidney Disease in Autosomal Dominant Polycystic Kidney Disease with Metformin and Other Therapies: An Update of New Insights.International journal of general medicine · 2021Review
- Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis.Oncology research · 2018Article
- Adjustment of serum HE4 to reduced glomerular filtration and its use in biomarker-based prediction of deep myometrial invasion in endometrial cancer.Oncotarget · 2017Article
- Elevated Squamous Cell Carcinoma Antigen, Cytokeratin 19 Fragment, and Carcinoembryonic Antigen Levels in Diabetic Nephropathy.International journal of endocrinology · 2017Article
- Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer.Contemporary oncology (Poznan, Poland) · 2016Article
- Role of β2-microglobulin in uremic patients may be greater than originally suspected.World journal of nephrology · 2015Review
- The role of epigenetics in kidney malignancies.Central European journal of urology · 2015Review
- Biomarkers of cardio-renal damage in chronic kidney disease: one size cannot fit all.Critical care (London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumour markers represent useful tools in diagnosis and clinical management of patients with cancer, because they are easy to use, minimally invasive, and easily measured in either blood or urine. Unfortunately, such an ideal marker, as yet, does not exist. Different pathological states may increase the level of a tumour marker in the absence of any neoplasia. Alternatively, low levels of tumour markers could be also found in the presence of neoplasias. We aimed at reviewing studies currently available in the literature examining the association between tumour markers and different renal impairment conditions. Each tumour marker was found to be differently influenced by these criteria; additionally we revealed in many cases a lack of available published data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.